patent/CR-20200484-A

http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CR-20200484-A

Outgoing Links

Predicate	Object
assignee	http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_05a203d85ee01909eaf728dc16f0f6cb
classificationCPCAdditional	http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-05
classificationCPCInventive	http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4725 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B59-002 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D409-14
classificationIPCInventive	http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-47
filingDate	2015-06-05-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor	http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f18bfad5b9e60f71873057aa98eaba8b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a7b67b3e501ba113af3dacaff4ca4594 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_51dcb0b873d649a18cb65880289180d2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2a44a81da69e26d17486edd364e325f3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_db08e93699f53b558c00a2fb406388d1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b76395b41b138346f9d81d5a95a31a60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aca0e4a5bdf94615f097ebfdd2f2d396
publicationDate	2021-04-26-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber	CR-20200484-A
titleOfInvention	SUBSTITUTE DIHYDROISOQUINOLINONE COMPOUNDS (Divisional 2016-0574)
abstract	<p> The present invention relates to compounds of the general Formula (I) wherein R <sup> 1 </sup>, R <sup> 2 </sup>, R <sup> 3 </sup>, R <sup> 4 </sup>, L, X, and Z are as defined herein, and salts thereof are pharmaceutically acceptable, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer. </p>
priorityDate	2014-06-17-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type	http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID426329550 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID56668956

Total number of triples: 32.